Key result
Ophthalmic timolol is linked to systemic toxicities, including bradycardia, heart failure, and respiratory distress.
Answers are grounded in this paper and cite their sources.
Since the introduction of ophthalmic timolol solution in 1978 there have been numerous reports of systemic toxicity associated with its use. The majority of the systemic side effects reported are the same as those associated with oral timolol. Several cases of respiratory distress have been described generally in patients with underlying restrictive airway disease. Cardiovascular effects range from effects on resting pulse rate to the development of overt bradycardia and heart failure. Central nervous system effects reported include fatigue, confusion, depression, and hallucinations. A variety of other systemic effects have also been described. Caution should be used when ophthalmic timolol is administered to elderly patients or those patients with contraindications to systemic beta-blockers.
No takes yet. Share an insight, caveat, or question.
Munroe et al. (1985) conducted a review in Systemic toxicity from ophthalmic timolol administration. Ophthalmic timolol solution was evaluated on Systemic side effects (respiratory distress, cardiovascular effects, central nervous system effects). Ophthalmic timolol administration since 1978 is associated with systemic side effects including respiratory distress, bradycardia, heart failure, and central nervous system toxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: